State Board of Administration of Florida Retirement System raised its holdings in Horizon Therapeutics PLC (NASDAQ:HZNP) by 107.4% in the fourth quarter, Holdings Channel reports. The fund owned 171,474 shares of the biopharmaceutical company’s stock after acquiring an additional 88,800 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Horizon Therapeutics were worth $6,207,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of the business. First Trust Advisors LP boosted its position in shares of Horizon Therapeutics by 87.7% during the fourth quarter. First Trust Advisors LP now owns 1,009,473 shares of the biopharmaceutical company’s stock worth $36,543,000 after buying an additional 471,687 shares during the period. Millennium Management LLC boosted its position in shares of Horizon Therapeutics by 48.6% during the third quarter. Millennium Management LLC now owns 1,006,265 shares of the biopharmaceutical company’s stock worth $27,400,000 after buying an additional 329,145 shares during the period. Columbus Circle Investors boosted its position in shares of Horizon Therapeutics by 33.9% during the fourth quarter. Columbus Circle Investors now owns 924,645 shares of the biopharmaceutical company’s stock worth $33,472,000 after buying an additional 234,097 shares during the period. California Public Employees Retirement System boosted its position in shares of Horizon Therapeutics by 30.6% during the fourth quarter. California Public Employees Retirement System now owns 505,935 shares of the biopharmaceutical company’s stock worth $18,315,000 after buying an additional 118,413 shares during the period. Finally, AMI Asset Management Corp acquired a new position in shares of Horizon Therapeutics during the fourth quarter worth about $11,317,000. 88.51% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:HZNP traded down $0.17 on Friday, hitting $35.67. The company’s stock had a trading volume of 168,442 shares, compared to its average volume of 1,501,887. The company has a current ratio of 2.33, a quick ratio of 2.23 and a debt-to-equity ratio of 0.87. The stock has a fifty day moving average of $36.39 and a two-hundred day moving average of $30.69. The firm has a market capitalization of $6.69 billion, a P/E ratio of 96.41, a price-to-earnings-growth ratio of 1.51 and a beta of 1.07. Horizon Therapeutics PLC has a one year low of $20.05 and a one year high of $39.10.
In other Horizon Therapeutics news, CEO Timothy P. Walbert sold 84,886 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $35.57, for a total value of $3,019,395.02. Following the sale, the chief executive officer now owns 987,991 shares in the company, valued at $35,142,839.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Brian K. Beeler sold 9,969 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $32.51, for a total value of $324,092.19. Following the completion of the sale, the executive vice president now owns 89,633 shares in the company, valued at approximately $2,913,968.83. The disclosure for this sale can be found here. Insiders sold 114,413 shares of company stock worth $4,039,099 in the last 90 days. Corporate insiders own 4.10% of the company’s stock.
Horizon Therapeutics Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Read More: What are the benefits of a balanced fund?
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.